Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics announces 1-for-24 reverse share split effective November 11, 2026

Neutral Impact 3 of 5 shareholder

Silexion Therapeutics, a Cayman Islands company trading on Nasdaq as SLXN, announced a 1-for-24 reverse share split of its ordinary shares. Split-adjusted trading begins at market open on November 11, 2026, and the company says the split is intended to help it regain compliance with Nasdaq's minimum bid price requirement.

Key points

  • Every 24 ordinary shares will be automatically combined into one share, with the par value increasing from $0.135 to $3.24 per share
  • Split-adjusted trading begins on the Nasdaq Capital Market at market open on November 11, 2026, under the existing ticker SLXN, with the split effective after market close on November 10, 2026
  • No fractional shares will be issued; DTC participants entitled to fractions will receive a rounded-up whole share, and shareholders need not take action

The filing

CompanySilexion Therapeutics Corp (SLXN)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:26 AM ET
Accession number0001178913-26-005089

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:35 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.